Promentis Pharmaceuticals, Inc. is developing innovative therapies for the treatment of neuropsychiatric disorders.
REDEFINE WHAT IS POSSIBLE®
Promentis Pharmaceuticals, Inc., a privately-held biopharmaceutical company is developing innovative therapies for neuropsychiatric disorders. The Company’s first indication is trichotillomania, a highly prevalent disorder for which there is no approved therapy. Alterations in glutamate signaling within brain regions implicated in urge control and executive function have been proposed to contribute to the underlying pathology of trichotillomania, as well as other obsessive-compulsive and addictive disorders, and other CNS conditions.
World Class Leadership and Ideas
Promentis Pharmaceuticals, Inc., a privately-held biopharmaceutical company developing innovative therapies for neuropsychiatric disordersLEARN MORE
Novel oral compounds engaging System xc -, a CNS target for diverse psychiatric disordersLEARN MORE
A growing roster of recognized leaders in the biopharmaceutical industry and clinical experts in CNS disordersLEARN MORE